Showing 1 to 10 of 14
| Title | Consultation | Type | Consultation end date | Sort date |
|---|---|---|---|---|
| Type 2 diabetes in adults: management - SGLT2 inhibitors for chronic kidney disease (update) | Draft guidance consultation | NICE guideline | Type:29 September 2021 | 20210929 |
| Asthma: diagnosis, monitoring and chronic asthma management | Draft scope consultation | NICE guideline | Type:30 September 2021 | 20210930 |
| Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (CDF Review TA600) ID1683 | Appraisal consultation | Technology appraisal guidance | Type:30 September 2021 | 20210930 |
| Pernicious anaemia | Draft scope consultation | NICE guideline | Type:06 October 2021 | 20211006 |
| Otitis media with effusion in under 12s: surgery | Draft scope consultation | NICE guideline | Type:06 October 2021 | 20211006 |
| Odevixibat for treating progressive familial intrahepatic cholestasis [ID1570] | Evaluation consultation: 1 | Highly specialised technology | Type:07 October 2021 | 20211007 |
| GID-MT561 ClearGuard HD Antimicrobial Barrier Cap for preventing haemodialysis catheter-related bloodstream infections | Draft guidance: 1 | Medical technologies guidance | Type:11 October 2021 | 20211011 |
| Colorectal cancer (QS update) | Quality standard consultation | Quality standard | Type:11 October 2021 | 20211011 |
| Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies [ID1557] | Appraisal consultation | Technology appraisal guidance | Type:12 October 2021 | 20211012 |
| Type 2 diabetes in adults: management (update) | Draft guidance consultation | NICE guideline | Type:14 October 2021 | 20211014 |